Skip to main content
Luke Nordquist, MD, Oncology, Omaha, NE

LukeTNordquistMD

Oncology Omaha, NE

Genitourinary Oncology, Hematologic Oncology

CEO and Medical Director, Urology Cancer Center and GU Research Network

Dr. Nordquist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Nordquist's full profile

Already have an account?

  • Office

    7710 Mercy Rd
    Ste 122
    Omaha, NE 68124
    Phone+1 402-393-3110
    Fax+1 402-393-4499

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
  • University of South Florida Morsani
    University of South Florida MorsaniResidency, Internal Medicine, 1998 - 2001
  • Creighton University School of Medicine
    Creighton University School of MedicineClass of 1998

Certifications & Licensure

  • NE State Medical License
    NE State Medical License 2003 - 2026
  • NY State Medical License
    NY State Medical License 2000 - 2005
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
  • QOPI Certification ASCO

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer  
    Mark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research

Press Mentions

  • Clarity Completes First Stage of Prostate Cancer Trial
    Clarity Completes First Stage of Prostate Cancer TrialMay 25th, 2023
  • Clarity's Theranostic Prostate Cancer Trial Advances to Cohort 2
    Clarity's Theranostic Prostate Cancer Trial Advances to Cohort 2May 24th, 2023
  • First Patient Treated in Clarity's Therapeutic Prostate Cancer Trial
    First Patient Treated in Clarity's Therapeutic Prostate Cancer TrialOctober 7th, 2022
  • Join now to see all

Professional Memberships